News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Vaccibody Receives Euros 2 Million to Develop Therapeutic Cervical Cancer Vaccine


11/12/2012 10:24:28 AM

OSLO, Norway--(BUSINESS WIRE)--Therapeutic vaccine company Vaccibody today announced that it has received a Euros 2 million grant from the Norwegian Research Council's BIA Program to develop a novel therapeutic vaccine against precancerous lesions of the cervix. The new vaccine, VB10.16, will be based on the company’s Vaccibody DNA vaccine platform, which targets antigen-presenting cells. The introduction of screening programmes has had a major impact on the incidence and mortality of invasive cervical cancer, and for example 11,000 new cases are detected in the US annually. However it is estimated that large numbers of older, disadvantaged and immigrant women remain outside such programmes.

Read at BioSpace.com


comments powered by Disqus
Vaccibody
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES